| 0.36 -0.011 (-3.04%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.45 | 1-year : | 0.5 |
| Resists | First : | 0.38 | Second : | 0.43 |
| Pivot price | 0.37  |
|||
| Supports | First : | 0.32 | Second : | 0.27 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.36 |
| MA(100) : | 0.51 |
MA(250) : | 0.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 39.6 |
| RSI | RSI(14): 41.8 |
|||
| 52-week | High : | 1.97 | Low : | 0.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SILO ] has closed above bottom band by 19.1%. Bollinger Bands are 64.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.39 | 0.39 - 0.39 |
| Low: | 0.35 - 0.35 | 0.35 - 0.35 |
| Close: | 0.36 - 0.36 | 0.36 - 0.36 |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Tue, 30 Dec 2025
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewswire
Mon, 29 Dec 2025
Silo Pharma receives extension from Nasdaq to regain minimum bid price compliance - Investing.com
Mon, 17 Nov 2025
Silo Pharma Partners with Allucent to Support Planned FDA - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1.028e+007 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 553 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.3e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 388.1 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 72100 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -136.69 |
| EBITDA (p.s.) | 74666.7 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.47 |
| Dividend | 0 |
| Forward Dividend | 592130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|